amide/infarction

The invention relates to amide and urea derivatives of the formula I in which R.sup.1 is 3-indolyl which is unsubstituted or mono- or disubstituted by A, AO, OH, Hal, CN, NO.sub.2, NH.sub.2, NHA, NA.sub.2, COA, CONH.sub.2, CONHA, CONA.sub.2, CH.sub.2 OH, CH.sub.2 OA, CH.sub.2 NH.sub.2, CH.sub.2 NHA,

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention belongs to 3-n-butyl-1-isoindolinone and the use thereof in preparation of drugs for preventing or treating cerebral infarction. 2. Description of the Related Art Cerebral infarction (CI), also known as cerebral ischemic stroke

This application is a U.S. national stage of International Application No. PCT/JP01/07977 filed Sep. 14, 2001. TECHNICAL FIELD The present invention relates to an amide derivative showing a C5a receptor antagonistic action and useful for the prophylaxis or treatment of autoimmune diseases such as

TECHNICAL FIELD The present invention relates to an amide derivative showing a C5a receptor antagonistic action and useful for the prophylaxis or treatment of autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic

FIELD OF THE INVENTION The present invention relates to 7a-amide substituted 6,6-difluro bicyclic himbacine derivatives, which are useful as protease activated receptor-1 (PAR-1) antagonists and might be expected to be cannabinoid (CB.sub.2) receptor inhibitors. PAR-1 receptors are also known in the

BACKGROUND OF THE INVENTION Endothelin is a 21-amino acid peptide produced by endothelial cells. The peptide is secreted not only by endothelial cells but also by tracheal epithelial cells or from kidney cells. Endothelin (ET-1 ) has a potent vasoconstrictor effect. The vasoconstricting effect is

BACKGROUND OF THE INVENTION Endothelin is a 21-amino acid peptide produced by endothelial cells. The peptide is secreted not only by endothelial cells but also by tracheal epithelial cells or from kidney cells. Endothelin (ET-1) has a potent vasoconstrictor effect. The vasoconstricting effect is

The invention relates to compounds of the formula I ##STR00002## in which R.sup.1 is H or A A is straight-chain or branched alkyl having from 1 to 10 carbon atoms, alkenyl having from 2 to 10 carbon atoms, alkoxy having from 1 to 10 carbon atoms or alkoxyalkyl having from 2 to 10 carbon atoms, X is

FIELD OF THE INVENTION This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,

FIELD OF THE INVENTION This invention relates to compounds that inhibit the secretion of apolipoprotein B, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia,

This application is the national phase under 35 U.S.C. .sctn. 371 of PCT International Application No. PCT/JP98/03422 which has an International filing date of Jul. 31, 1998, which designated the United States of America. 1. Technical Field The present invention relates to a novel N-acylamino acid

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

TECHNICAL FIELD The present invention relates to a novel butadiene derivative and a novel pyrrolidine derivative, both having excellent activity for inhibiting the activity or production of type 1 plasminogen activator inhibitor (PAI-1) in living body and being useful as an antithrombotic agent, and

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for preventing and/or treating osteoporosis and other disease states in animal subjects, utilizing organic boron compounds. 2. Description of the Related Art The adult skeleton is composed of 80% cortical